Plasma Protein Fraction

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Dosage
  • Special Considerations

Brand Names


Finland: Octaplas; Greece: Plasmanate; Hungary: Octaplas; Ireland: Octaplas; Netherlands: Octaplas; Portugal: Novoplas, Octaplas; Romania: Octaplas; Slovakia: Geloplasma; Sweden: Octaplas; UK: Octaplas.

Latin America

Mexico: Octaplas.


Japan: Albuminat, Plasma Protein Fraction.

Drug combinations


Pharmacologic Category

Blood Derivatives. (ATC-Code: B05AA02).

Mechanism of action

Sterile 5% solution of selected proteins prepared from pooled plasma obtained from healthy human donors, a protein colloid with pharmacologic properties similar to those of its primary constituent, albumin.

Therapeutic use

Plasma volume expansion and maintenance of cardiac output in treatment of certain types of shock or impending shock.

Pregnancy and lactiation implications

Reproduction studies not conducted. Unknown whether it can cause fetal harm when administered to pregnant women; protein colloid should be used during pregnancy only when clearly needed.

Unlabeled use


Hypersensitivity to plasma protein fraction or any component of the formulation. Patients on cardiopulmonary bypass. Severe anemia. Congestive heart failure. Increased blood volume.

Warnings and precautions

Rapid infusions may cause hypotension. Product of human plasma (may potentially contain infectious agents which could transmit disease). May be useful for initial therapy of shock due to dehydration or infection in children. Plasma protein fraction does not contain coagulation factors and does not correct coagulation disorders.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart